Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 3;14(7):716.
doi: 10.3390/jpm14070716.

Retention Rate of Ixekizumab in Psoriatic Arthritis: A Real-World Study

Elisa Bellis  1 , Piero Ruscitti  2 , Denise Donzella  1 , Gloria Crepaldi  1 , Valeria Data  1 , Marinella Gammino  1 , Mariele Gatto  1 , Valeria Guardo  1 , Claudia Lomater  1 , Elena Marucco  1 , Marta Saracco  1 , Annamaria Iagnocco  1
Affiliations

Retention Rate of Ixekizumab in Psoriatic Arthritis: A Real-World Study

Elisa Bellis et al. J Pers Med. .

Abstract

We aimed to examine the drug retention rate (DRR) of the interleukin-17 inhibitor ixekizumab in a real-world monocentric cohort of psoriatic arthritis (PsA) patients and to assess the predictors of drug discontinuation. Consecutive PsA patients who underwent treatment with ixekizumab from October 2019 to February 2023 were enrolled in this observational, retrospective, monocentric study. Clinical records were assessed at baseline and throughout the follow-up period. We collected sociodemographic data, smoking habits, body mass index, the presence of Human Leukocyte Antigen B27, comorbidities, disease involvement and duration, previous therapy, discontinuation of ixekizumab, reasons for discontinuation, and adverse events (AEs). DRR was evaluated as time to drug discontinuation and assessed through Kaplan-Meier curves. Baseline factors predicting drug discontinuation were investigated through logistic regression models. Eighty PsA patients were included in this study. Ixekizumab was administered at a dose of 160 mg by subcutaneous injection at baseline, followed by 80 mg every four weeks thereafter. Ixekizumab had a 38-month-cumulative DRR of 43.8%, accounting for both inefficacy and AEs. When considering only inefficacy, the DRR was 62.6%. Comorbidities (p = 0.665), obesity (p = 0.665), smoking (p = 0.884), disease duration ≤ 2 years (p = 0.071), axial (p = 0.131) and skin involvement (p = 0.460), and previous therapies, including conventional synthetic (p = 0.504) and biological (p = 0.474) Disease-Modifying Antirheumatic Drugs (bDMARDs), as well as the number of previous bDMARDs or targeted synthetic Disease-Modifying Antirheumatic Drugs (tsDMARDs), did not significantly affect the DRR (p = 0.349). Multivariate analysis found no independent predictors of drug discontinuation. The most frequent AEs leading to discontinuation were skin reactions; no severe infections were observed. In our real-world study, comorbidities, disease duration, and previous therapies did not affect the DRR of ixekizumab. Ixekizumab had a favorable safety profile, with no severe AEs observed.

Keywords: drug retention rate; ixekizumab; psoriatic arthritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following conflicts of interest. E.B.: Honoraria: BMS, Novartis. P.R.: Honoraria: Abbvie, BMS, Ely Lilly, Janssen Novartis, Sobi; educational grants: BMS; research support: Pfizer. D.D.: Honoraria: Janssen. G.C.: advisory boards: Novartis, AbbVie, Alfa-sigma; speakers’ bureau: Janssen, Galapagos, Eli-Lilly, BMS. V.D.: no conflict of interest. M. Gammino: no conflict of interest. M. Gatto: Honoraria, speakers bureau from: GSK, Astrazeneca, Janssen. V.G.: no conflict of interest. C.L.: Honoraria, advisory boards, speakers’ bureau, educational grants, research support from: BMS, Pfizer, AbbVie, Janssen, Eli-Lilly. E.M.: no conflict of interest; M.S.: no conflict of interest. A.I.: Honoraria, advisory boards, speakers’ bureau, educational grants, research support from: AbbVie, Alfa-sigma, BMS, Celgene, Celltrion, Eli-Lilly, Galapagos, Gilead, MSD, Janssen, Novartis, Pfizer, Sanofi Genzyme, SOBI.

Figures

Figure 1
Figure 1
Cumulative DRR of ixekizumab: Inefficacy and AEs (a) and Inefficacy (b). DRR, drug retention rate; AEs, adverse events.
Figure 2
Figure 2
DRR of ixekizumab according to comorbidities (a), obesity (b), and smoking (c). DRR, drug retention rate; BMI, body mass index.
Figure 3
Figure 3
DRR of ixekizumab according to disease duration (a,b), axial disease (c), and skin involvement (d). DRR, drug retention rate.
Figure 4
Figure 4
DRR of ixekizumab according to previous therapies: csDMARDs (a), MTX (b), bDMARDs (c), TNFi (d). csDMARDs, conventional synthetic Disease-Modifying Antirheumatic Drugs; MTX, methotrexate; bDMARDs, biologic Disease-Modifying Antirheumatic Drugs; TNFi, tumor necrosis factor inhibitor; DRR, drug retention rate.
See this image and copyright information in PMC

References

    1. Rida M.A., Chandran V. Challenges in the Clinical Diagnosis of Psoriatic Arthritis. Clin. Immunol. 2020;214:108390. doi: 10.1016/j.clim.2020.108390. - DOI - PubMed
    1. Haroon M., Kirby B., FitzGerald O. High Prevalence of Psoriatic Arthritis in Patients with Severe Psoriasis with Suboptimal Performance of Screening Questionnaires. Ann. Rheum. Dis. 2013;72:736–740. doi: 10.1136/annrheumdis-2012-201706. - DOI - PubMed
    1. Moshrif A., Mosallam A., Mohamed E.E.M., Gouda W., Doma M. Subclinical Enthesopathy in Patients with Psoriasis and Its Association with Other Disease Parameters: A Power Doppler Ultrasonographic Study. Eur. J. Rheumatol. 2017;4:24–28. doi: 10.5152/eurjrheum.2017.16049. - DOI - PMC - PubMed
    1. Naredo E., Moller I., De Miguel E., Batlle-Gualda E., Acebes C., Brito E., Mayordomo L., Moragues C., Uson J., De Agustin J.J., et al. High Prevalence of Ultrasonographic Synovitis and Enthesopathy in Patients with Psoriasis without Psoriatic Arthritis: A Prospective Case-Control Study. Rheumatology. 2011;50:1838–1848. doi: 10.1093/rheumatology/ker078. - DOI - PubMed
    1. Zuliani F., Zabotti A., Errichetti E., Tinazzi I., Zanetti A., Carrara G., Quartuccio L., Sacco S., Giovannini I., Stinco G., et al. Ultrasonographic Detection of Subclinical Enthesitis and Synovitis: A Possible Stratification of Psoriatic Patients without Clinical Musculoskeletal Involvement. Clin. Exp. Rheumatol. 2019;37:593–599. - PubMed

LinkOut - more resources